Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Print
Dongliang Zhuang, PhD
TRACON Pharmaceuticals Inc
Poster(s):
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY